Who are Efgartigimod's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vyvgart, IV efgartigimod, Efgartigimod PH20 SC, RYSTIGGO, Blenrep, UPLIZNA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/efgartigimod.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Efgartigimod — Competitive Intelligence Brief

Efgartigimod (Efgartigimod) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endoglycosidase [EPC]. Area: Immunology.

marketed Endoglycosidase [EPC] FcRn Immunology Biologic Live · refreshed every 30 min

Target snapshot

Efgartigimod (Efgartigimod) — M. Peter Marinkovich. Efgartigimod alfa binds to FcRn, reducing circulating IgG, while hyaluronidase increases subcutaneous permeability.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Efgartigimod TARGET	Efgartigimod	M. Peter Marinkovich	marketed	Endoglycosidase [EPC]	FcRn
Vyvgart	EFGARTIGIMOD ALFA	Argenx Bv	marketed	Endoglycosidase [EPC]	IgG receptor FcRn large subunit p51	2021-01-01
IV efgartigimod	IV efgartigimod	Rambam Health Care Campus	marketed	FcRn inhibitor	Neonatal Fc receptor (FcRn)
Efgartigimod PH20 SC	Efgartigimod PH20 SC	argenx	marketed	FcRn antagonist	Neonatal Fc receptor (FcRn)
RYSTIGGO	ROZANOLIXIZUMAB-NOLI	UCB INC	marketed	Neonatal Fc Receptor Blocker [EPC]	IgG receptor FcRn large subunit p51
Blenrep	Blenrep	Duke University	marketed		Low affinity immunoglobulin gamma Fc region receptor III-A, High affinity immunoglobulin gamma Fc receptor I, IgG receptor FcRn large subunit p51
UPLIZNA	UPLIZNA	Amgen	marketed	FcRn antagonist	FcRn (neonatal Fc receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Endoglycosidase [EPC] class)

Adrienne G. Waks · 1 drug in this class
Argenx Bv · 1 drug in this class
Genentech, Inc. · 1 drug in this class
M. Peter Marinkovich · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Efgartigimod — Competitive Intelligence Brief. https://druglandscape.com/ci/efgartigimod. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab